| Literature DB >> 30168781 |
Naoya Kikuchi1, Masafumi Uesugi1, Masao Koda2, Tomoaki Shimizu1, Kohei Murakami1, Mamoru Kono1, Haruka Tanaka1, Masashi Yamazaki2.
Abstract
The use of methotrexate (MTX) to treat rheumatoid arthritis (RA) is increasing. Recently, MTX-associated lymphoproliferative disorder (MTX-LPD) has been frequently reported as lymphoma occurring during MTX therapy. The authors report their experience with a relatively rare case of MTX-LPD presenting in the lumbar spine. The patient, a 73-year-old woman who experienced low-back pain while receiving MTX therapy for RA, was suspected of having developed MTX-LPD based on her medical history, images of the L1 vertebra, and transpedicular biopsy results. One week after discontinuing MTX, the patient's low-back pain reportedly improved. The woman was diagnosed with MTX-LPD based on histopathological findings. MTX discontinuation alone coincided with spontaneous tumor regression. Because MTX-LPD can occur in tissues other than lymph nodes, such as in bones and joints, it is a disease that should be considered when diagnosing spinal tumors in patients receiving MTX therapy.Entities:
Keywords: EBV = Epstein-Barr virus; LPD = lymphoproliferative disorder; MTX = methotrexate; MTX-LPD = MTX-associated LPD; RA = rheumatoid arthritis; lumbar spine; lymphoproliferative disorder; methotrexate; oncology; rheumatoid arthritis
Mesh:
Substances:
Year: 2018 PMID: 30168781 DOI: 10.3171/2018.4.SPINE1860
Source DB: PubMed Journal: J Neurosurg Spine ISSN: 1547-5646